Regeneron Pharmaceuticals Inc Oncology Investor Event at ESMO Transcript
Good day, and thank you for standing by. Welcome to the Regeneron Oncology Investor Event, ESMO 2021. (Operator Instructions) Please be advised today's conference may be recorded. (Operator Instructions) I'd now like to hand the conference over to Justin Holko, Vice President, Investor Relations.
Thank you, Liz, and welcome to everybody to join this call this morning. Joining me on the call today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; and Dr. Israel Lowy, Senior Vice President of Transitional Sciences and Oncology. After our prepared remarks, we'll open the call for Q&A.
Before handing the call over to George, however, I would like to remind you that remarks made on today's call include forward-looking statements about Regeneron, including those related to Regeneron's business and research and development programs, anticipated milestones regulatory matters.
Each forward-looking statement is subject to risks and uncertainties that could cause
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |